NCT06322446Active, not recruiting
Exercise in People With Cystic Fibrosis on CFTR Modulator Therapy
Effects of a Strength Exercise Program on Muscular Health in People With CF Treated With Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Receptor (CFTR)
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
Recently, the treatment of Cystic Fibrosis (CF) incorporated new modulators/enhancers of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). It is thus increasingly important to study the side effects of these drugs, their extrapulmonary effects and possible interaction with other drugs and with exercise. For this purpose, a randomized controlled trial is proposed to determine the effects of a telematic exercise intervention on muscle health, in a group of 48 children and adolescents with CF treated with these new generation CFTR modulators. They will be randomly assigned to two groups (exercise and control group). The effect of the intervention will be analysed measuring the variables of muscle health, cardiorespiratory fitness, lung function, body composition, inflammatory biomarkers and miRNAs. After completion of the intervention program, adherence to exercise and clinical evolution after one year will be analysed.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 22 Feb 2024
- Start date
- 27 Feb 2024
- Primary completion date
- 4 Jun 2026
- Lead sponsor
- Universidad Politecnica de Madrid
- Diseases
- Cystic fibrosis
- NCT number
- NCT06322446
What you commit to
- Study type: Interventional
- Planned participants: 48
- From 27 Feb 2024 to the primary completion date, 4 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- CF patient with incomplete dosing of modulator therapy;
Other illness
- with a diagnosis of other cardiorespiratory lung diseases progressing to a symptom of persistent respiratory dysfunction.
- CF patient with cognitive impairment;
Other
- CF patients with symptoms of pulmonary exacerbation during the last four weeks.
- CF patients with musculoskeletal alterations that influence assessments.
- CF patient who is pregnant during the time of the study
Who the study is looking for
- patients diagnosed with CF.
- patients between 6-20 years of age.
- patients receiving treatment with new CFTR protein modulating medication
- reading, acceptance and signing of the informed consent form.
Age in the registry: 6 years to 20 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Facultad de Ciencias de la Actividad Física y Deporte - INEF UPM Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.